knowledge -WSS

knowledge

author：leisure time 2025-09-06 01:55:27 - browse：16925

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Cue Health's Covid

focus

WSS

Cue Health's Covid

Chemotherapy before breast cancer surgery might fuel metastasis

Welsh Carson private equity firm escapes from FTC antitrust case

Crowdfunding for medical bills sidesteps core problem, author says

Brain technologies pose threats that are all too real, experts warn

Medical bills so high, Medicare adding extra digits to claim forms

entertainment

knowledge

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Has Bernie Sanders reached the limit of his pharma bullying effort?

As demand for Covid shots wanes, Moderna seeks its next success

Warren pushes Witty on UnitedHealth's control over physicians

Affirmative action in medical school literally saved lives

FTC falls short on scrutinizing hospital mergers, study says

Bright Health sells Medicare Advantage business to Molina

HHS's proposed rule does nothing to address the climate crisis

United colonoscopy coverage change 'may cost lives,' doctors say

BIO to announce reorganization, senior leaders expected to depart

focus

As billionaires fund anti

Cancer researcher Catriona Jamieson is sending tumors into space

Can gargling with Listerine treat gonorrhea of the mouth?

The creative science of coining drug names

AI for drug discovery: Experts on separating hype from reality

AltruBio raises $225 million to develop ulcerative colitis drug

hotspot

focus

focus

hotspot